Gyre Therapeutics is trading at $5.05, up 10.87%, with broader market strength likely contributing to the move.
- Major U.S. indices are higher, supporting a likely market-sentiment contribution; no fresh company-specific announcement or clear catalyst was identified.
- The company’s investor-relations page lists earlier releases, and morning market coverage reported a premarket gain without identifying a company catalyst.
- The stock is rebounding after its 28.94% decline on October 30.